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Fungi are increasingly recognized as major pathogens in immunocompromised individuals.
With the increase in the number of fungal infections each year and the development
of resistance to current therapy, new approaches to treatment including stimulation of
the immune response in addition to concurrent pharmacotherapy is ongoing. The most
common invasive fungal infections are caused by Candida spp., Aspergillus spp., and
Cryptococcus spp. Amphotericin B (AmB) has remained the cornerstone of therapy against
many fulminant fungal infections but its use is limited by its multitude of side effects.
Echinocandins are a newer class of antifungal drugs with activity against Candida spp. and
Aspergillus spp. and constitutes an alternative to AmB due to superior patient tolerability
and fewer side effects. Due to their oral delivery, azoles continue to be heavily used for
simple and complex diseases, such as ﬂuconazole for candidal vaginitis and voriconazole
for aspergillosis. The objective of this paper is to present current knowledge regarding
the multiple interactions between the broad spectrum antifungals and the innate immune
response, primarily focusing on the toll-like receptors.
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INTRODUCTION
Fungal species are ubiquitous in the environment an estimated
1.5 million are known to exist (Hube, 2009). Only a few species
are actually true pathogens in humans. Opportunistic fungi can
cause life threatening infections ranging from superﬁcial to deep
seated infections in immunocompromised patients. In develop-
ing countries fungal infections affect both immunocompromised
and immunocompetent individuals in areas that are endemic to
mycoses (Brown et al., 2012). Fungal infections have increased
over the last few decades and this can be correlated to increased
invasive medical management, immunosuppressed patients either
from acquired infections or from treatment induced deﬁciencies
(Pfaller and Diekema, 2007). Interestingly, fungi are the fourth
main cause of hospital acquired infections in populations “at-
risk” despite the availability of antifungal treatment. This point
illustrates the need for further study to identify more efﬁcient
ways to combat these interesting pathogens. It is often chal-
lenging to treat fungal infections because current methods to
identify particular species are not always reliable or accurate result-
ing in delayed or inappropriate treatment (Perlin, 2011; Pfaller,
2012).
Amphotericin B (AmB) is a polyene antifungal agent ﬁrst iso-
lated from Streptomyces nodosus in 1955, from Venezuelan soil
samples near the Orinoco River region (Dutcher, 1968). AmB
is selectively toxic toward fungal cells, displaying high afﬁn-
ity for ergosterol, subsequently destabilizing fungal membranes
(refer to Table 1 – “Commonly used systemic antifungal drugs”
for mechanism of action of common antifungals). It is primar-
ily used in systemic fungal infections caused by Histoplasma,
Coccidioides, Candida, Blastomyces, Rhodotorula, Cryptococcus,
Sporothrix, Mucor and Aspergillus spp. and the drug has remained
the cornerstone of the therapy against fulminant fungal infections
(Ellis, 2002). AmB also has activity against some protozoans, and
prions (Adjou et al., 1997; Kafetzis et al., 2005). AmB is ampho-
teric as well as amphipathic, has a low therapeutic index, and is
associated with signiﬁcant dose-related nephrotoxicity (Fanos and
Cataldi, 2000), as well as acute, infusion-related febrile reactions
(Khoo et al., 1994). Lipid-based formulations of AmBhave allowed
patients to receive higher doses while sparing toxicity (Hiemenz
and Walsh, 1996). AmB also stimulates the production of inﬂam-
matory cytokines (TNF-α, IL-1β, IL-6, IL-8), chemokines (MCP-1,
MIP-1β, IL-8), prostaglandins, and nitric oxide (Cleary et al., 1992;
Arning et al., 1995; Razonable et al., 2005). In addition to its direct
antifungal activity,AmB activates toll-like receptors (TLRs), which
contribute to the cytokine responses.
Echinocandins are a newer class of antifungal drugs that display
a uniquemechanism of action, inhibiting the synthesis of 1,3-β-D-
glucan in the cell wall, through the inhibition of the enzyme 1,3-β
glucan synthase (Morris and Villmann, 2006; Fera et al., 2009).
Besides having a structural role, β-D-glucan also demonstrates
potent immunostimulatory properties mediated by the innate
immune receptor Dectin-1, as well as TLRs and C-type lectin
receptors, which are expressed on host cells (Brown, 2006;Wheeler
et al., 2008). Following binding, echinocandins induce the acti-
vation of phagocytic and proinﬂammatory responses (Dennehy
and Brown, 2007). The echinocandins’ antimicrobial spectrum
includes most of the Candida spp. strains,Aspergillus spp., and has
some activity against Pneumocystis jiroveci (Denning, 2002). The
advantages of echinocandins include long half-life allowing daily
dosing, no dose adjustment in renal impairment or hemodialysis,
minimal adverse effects, and limited drug interactions (Denning,
2002).
Human TLRs are closely related to the toll receptors in
Drosophila melanogaster, and they are important for defense
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Table 1 | Commonly used systemic antifungal drugs [as reviewed by Lewis (2011)].
Mechanism Class Drugs
Cell membrane
Ergosterol inhibitors/binders
Azoles (14-α demethylaseinhibitors) Triazoles
Fluconazole, itraconazole, voriconazole, posaconazole,
Polyenes (ergosterol binding) Amphotericin B
Allylamines (squalene monooxygenase) Terbinaﬁne
Cell wall
B-1,3 D-glucan synthesis
Echinocandins (β-1,3 D-glucan synthesis inhibitors) Anidulafungin, caspofungin, micafungin
Intracellular Pyrimidine analogs/thymidylate synthase inhibitor Flucytosine
Mitotic inhibitor Griseofulvin
against microbial infection (Medzhitov et al., 1997). TLRs are a
class of proteins that play a critical role in the immune systems
response to invading pathogens. They are found in tissues involved
in immune function, as well as in tissues exposed to the exter-
nal environment (the respiratory and the gastrointestinal tract).
Ten TLRs have been identiﬁed in humans (TLR1–TLR10). They
recognize structural repeating sequences known as pathogen-
associated microbial patterns which are expressed by microbial
pathogens, or danger-associated molecular patterns that are
endogenous molecules released from necrotic cells and stimu-
late the release of inﬂammatory cytokines (Newton and Dixit,
2012). Some of the most important TLRs are TLR1 which recog-
nize pathogen-associated molecular pattern with a speciﬁcity for
Gram-positive bacteria, TLR2s that recognizemany bacterial, fun-
gal, viral, and certain endogenous substances, TLR4 which detects
lipopolysaccharide fromGram-negative bacteria and TLR9, which
is expressed by numerous cells of the immune system such
as dendritic cells, B lymphocytes, monocytes, and natural
killer cells and recognizes unmethylated CpG sequences in DNA
molecules.
AMPHOTERICIN B AND TLRs
AmB stimulates multiple TLRs, namely TLR1, TLR2, TLR4. Sau
et al. (2003) demonstrated that TLR2 and CD14 receptors play
an important role in the release of the inﬂammatory cytokines
TNF-α and IL-8. Moreover, TLR2 has a key role in the release of
IL-1β. Peritoneal macrophages, isolated from murine cells lack-
ing TLR2, failed to release TNF-α, IL-1β, and IL-8 in response to
AmB stimulation, in comparison with peritoneal macrophages
isolated from TLR2 positive mice, which displayed increased
inﬂammatory cytokine production. Furthermore AmB induced
TNF-α productionwas suppressed in peritonealmacrophages that
expressed mutant, non-functional TLR4. However, this effect was
observed only at higher AmB concentrations. The authors of the
study also demonstrated that TLR response to AmB was CD14
dependent. Therefore, CD14 positive cells produced TNF-α when
stimulated by AmB, whereas those which were CD14 negative did
not. Interestingly, lipid formulations of AmB did not elicit sig-
niﬁcant cytokine production and release from murine peritoneal
macrophages, possibly due to the low concentration of unbound,
non-lipid associated AmB (Sau et al., 2003).
The essential role of TLR1 in AmB induced cell activation was
proven by Razonable et al. (2005) using THP1monocytic cell line.
The preincubation of THP1 cells with murine anti-human TLR1
monoclonal antibody (anti-TLR1 MAb) reduced the production
of IL-6, IL-8, and TNF-α in response to AmB. Anti-TLR1 MAb
also inhibited IL-8 secretion in response to the TLR2–TLR1 ligand
Pam-3-Cys. Additionally, IL-8 inhibitionwith anti-TLR1MAbwas
superior than with anti-TLR2MAb and the addition of anti-TLR1
MAb augmented the degree of IL-8 inhibition by anti-TLR2 MAb
(Razonable et al., 2005).
To further characterize the inﬂuence of AmB on TLRs,
Bellocchio et al. (2005) showed that the expression of TLR2 and
TLR4 was activated upon exposure of neutrophils (human and
mice) to Aspergillus conidia. However, TLR4 was only stimulated
upon exposure to the fungal hyphae. AmB increased the expression
of TLR2, while liposomal AmB increased the expression of TLR4
in neutrophils. Using puriﬁed murine neutrophils, the authors
were able to demonstrate that both TLR4 activation and liposomal
AmB deter production of pro-inﬂammatory cytokines and stim-
ulate anti-inﬂammatory cytokines. Additionally, in the absence of
TLR4, liposomal AmB acts like deoxycholate AmB, stimulating the
release of inﬂammatory cytokines (Bellocchio et al., 2005).
In another study published by Matsuo et al. (2006) using
monocyte-like cell lines, the authors demonstrated that AmB
phosphorylates p65 of nuclear factor-kappaB. Further evidence in
the study suggested that this leads to stimulation of proinﬂamma-
tory cytokine production, mediated by receptors including TLR2
and NF-kappaB (Matsuo et al., 2006).
ECHINOCANDINS AND TLRs
The inﬂuence of echinocandins on the innate immune recep-
tors is achieved through the inﬂuence of these antifungals on
β-D-glucan. A report published by Moretti et al. (2012) demon-
strated that caspofungin inﬂuenced TLR2/Dectin-1 interactions,
as wells as Dectin-1 engagement with TLR4 and TLR9. Using
an invasive aspergillosis model in which two different strains
of Dectin-1/TLR2 deﬁcient murines were treated with caspo-
fungin, the authors found that at lower concentration of the
drug (0.1 mg/kg) the restricting activity on fungal growth was
preserved, as well as the inﬂammatory cell recruitment. How-
ever, this was dependent on the genetic background of the
host (C57BL/6 responded to treatment with caspofungin but
BALB/c did not). At higher doses (5 mg/kg) both types of
mutant mice had signiﬁcant restriction of fungal growth and
reduction of inﬂammatory cell recruitment. Both the protective
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(at 0.1 mg/kg) and the exacerbating (at 5 mg/kg) effects of
caspofungin were lost in TLR2 deﬁcient mice, indicating that
TLR2 is required for the antifungal activity of echinocan-
dins against aspergillosis. Furthermore, using TLR4 and TLR9
deﬁcient mice with invasive aspergillosis, the authors showed
that TLR4 contributes to the protective effect and TLR9 con-
tributes to the exacerbating effect of caspofungin (Moretti et al.,
2012).
Similarly, using a murine model of infective aspergillosis,
Moretti et al. (2013) studied the immunomodulatory activity of
echinocandins. Micafungin controlled cytokine response to A.
fumigatus by decreasing the expression of TNF-α and increas-
ing IL-10 release. The anti-inﬂammatory activity of micafun-
gin required IL-10 and occurred through signaling via the
TLR2/dectin-1 and TLR3/TRIF pathways (Moretti et al., 2013).
In another article published by Salvenmoser et al. (2010),
caspofungin treatment resulted in the highest upregulation of
TLR2 by A. fumigatus whereas exposure of C. albicans to caspo-
fungin let to the signiﬁcant upregulation of TLR4 and TLR9.
AZOLES AND TLRs
There seems to be a similar interaction of azoles on TLR and
subsequent immunomodulation, however, the data is limited.
In previously mentioned article published by Salvenmoser et al.
(2010), voriconazole treatment upregulated TLR2, TLR4, and
TLR9 by A. fumigatus. In another study by Simitsopoulou et al.
(2008) an additive antifungal effect was demonstrated when
voriconazole was combined with monocytes and A. fumigatus
hyphae. Both A. fumigatus hyphae and voriconazole induced
increased expression of TLR2 as well as TNF-α in monocytic cells
compared to untreated cells. The effects were seen when both were
used independently but more signiﬁcantly when used in combi-
nation. In contrast, TLR4 expression was not increased by either
voriconazole or fungal hyphae. In addition, signiﬁcantly more
NF-kappaB was translocated to monocyte cell nuclei treated with
voriconazole than untreated cells. The study suggests that TLR2
signaling, TNF-α, and NF-kappaB activation in the presence of
voriconazole proposes an immunomodulation effect leading to
a more efﬁcient response to A. fumigatus (Simitsopoulou et al.,
2008).
DISCUSSION
Fungi are increasingly recognized asmajor pathogens in immuno-
compromised individuals. Risk factors for invasive fungal infec-
tions include prolonged neutropenia, hematological malignancy,
transplantation (particularly bone marrow transplant), cytotoxic
drugs, and steroid therapy (Enoch et al., 2006).
The most common invasive fungal infections are candidiasis,
followed by aspergillosis and cryptococcosis (Shoham and Marr,
2012). Disseminated candidiasis is associated with a mortality in
excess of 25% (Kibbler et al., 2003), and represents the fourth
most common cause of nosocomial blood stream infection in
United States (Wenzel and Edmond, 2001). Invasive aspergillo-
sis is also associated with signiﬁcant morbidity and mortality,
lung, and heart–lung transplant recipients being at greatest risk of
infection, affecting 14–18%of patients (Hagerty et al., 2003). AmB
remains themost effective drug against fulminant fungal infections
but its use is limited by the multitude of side effects including
nephrotoxicity, infusion related toxicity, electrolyte abnormali-
ties, and others. Echinocandins are a newer class of antifungal
drugs with activity against Candida spp. and Aspergillus spp. and
constitutes an alternative to AmB due to a superior toleration
proﬁle and less side effects. The azoles used for systemic fun-
gal infections are triazoles and include ﬂuconazole, itraconazole,
voriconazole, and posaconazole. They inhibit the cytochrome
P450 dependent enzyme lanosterol 14-alpha-demethylase, thus
inhibiting the synthesis of ergosterol, which represents a vital com-
ponent of the cellular membrane of fungi (Zonios and Bennett,
2008). As outlined in this review, AmB, echinocandins, and some
of the studied azoles have long been used and their mechanisms
of action against fungi are well established. However, these drugs
also act on components of the innate immune system aiding in
the body’s natural defense against the infecting pathogens. As out-
lined in this review, TLRs seem to be signiﬁcant components in
this setting. The innate immune response has physical barriers
that provide protection from the environment which include the
skin and mucus membranes of the respiratory, gastrointestinal,
and genito-urinary tracts. Once fungi have invaded these barri-
ers they encounter a multitude of innate defenses that include
phagocytes, natural killer cells, T cells, B cells, and endothe-
lial cells (Blanco and Garcia, 2008). Generally the interaction
between antifungal therapy and the immune system is syner-
gistic. Chemotactic factors are produced at the site of fungal
infections, leading to activation of the complement pathway. The
synthesis of these chemotactic factors is stimulated by pathogen
associated molecular patterns, (PAMPs) that are recognized by
pattern recognition receptors (PRRs). PRRs include TLRs. PRRs
and TLRs activate PAMPs which signal the synthesis and release
of pro-inﬂammatory cytokines that activate the adaptive immu-
nity. A fungal pathogen activates multiple PRRs, which alerts
the immune system to respond with a broad range of possibili-
ties (Janeway and Medzhitov, 2002; Roeder et al., 2004; Romani,
2004). Antimicrobial peptides are other components of the innate
immune system that have an antimicrobial effect against fungi.
There exact mechanism is not known but they are likely to activate
andmediate the innate and adaptive immune response in infection
and inﬂammation. They also inactivate fungi by directly affecting
theirmembrane (Ganz, 2003;Aerts et al., 2008, Steinstraesser et al.,
2008).
Polymorphisms in TLR genes have been associated with a sus-
ceptibility to fungal infections. The type of infection depends
on which TLR has mutated. Recognition of Candida normally
occurs through PRRs such as TLRs. Plantinga et al. (2012) ana-
lyzed that TLR single nucleotide polymorphisms (SNPs) [R80T,
S248N, 1602S] on TLR1 were associated with candidemia in white
populations. This was not present in African American popula-
tions but this was attributed to the lower power in the smaller
study population. These polymorphisms also impaired cytokine
release by monocytes (Plantinga et al., 2012).
Invasive aspergillosis is a particular concern in patients that
have had hematopoietic-cell transplants, with its incidence rate
increasing. Despite the availability of new medications (azoles
and echinocandins) their outcome remains poor (Marr et al.,
2002). Aspergillosis activates the immune system through TLR4.
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Bochud et al. (2008) analyzed that donor TLR4 haplotypes (S3,
S4) increased the risk of invasive aspergillosis among recipients of
allogenic hematopoietic-cell transplants.
The ability of antifungals to simultaneously elicit an efﬁcient
immune response should be researched further for the potential
development of new drugs to induce effective activation of the
innate immune system via TLRs and subsequent pathways that
may synergistically help clear fungal infections.
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